Measurement of advanced glycation end products may change NASH management

Editorial

. 2007 Sep;22(9):1354-5.

doi: 10.1111/j.1440-1746.2007.05019.x.

Editorial

Valerio Nobili et al. J Gastroenterol Hepatol. 2007 Sep.

. 2007 Sep;22(9):1354-5.

doi: 10.1111/j.1440-1746.2007.05019.x.

No abstract available

Comment on

Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis.
Hyogo H, Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, Ochi H, Nonaka M, Nabeshima Y, Inoue M, Ishitobi T, Chayama K, Tazuma S. Hyogo H, et al. J Gastroenterol Hepatol. 2007 Jul;22(7):1112-9. doi: 10.1111/j.1440-1746.2007.04943.x. Epub 2007 Jun 7. J Gastroenterol Hepatol. 2007. PMID: 17559366

Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.
de la Monte SM, Longato L, Tong M, Wands JR. de la Monte SM, et al. Curr Opin Investig Drugs. 2009 Oct;10(10):1049-60. Curr Opin Investig Drugs. 2009. PMID: 19777393 Free PMC article. Review.
Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis.
Lyn-Cook LE Jr, Lawton M, Tong M, Silbermann E, Longato L, Jiao P, Mark P, Wands JR, Xu H, de la Monte SM. Lyn-Cook LE Jr, et al. J Alzheimers Dis. 2009;16(4):715-29. doi: 10.3233/JAD-2009-0984. J Alzheimers Dis. 2009. PMID: 19387108 Free PMC article.
Epidemilogical trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer's disease, diabetes mellitus, and non-alcoholic steatohepatitis.
de la Monte SM, Neusner A, Chu J, Lawton M. de la Monte SM, et al. J Alzheimers Dis. 2009;17(3):519-29. doi: 10.3233/JAD-2009-1070. J Alzheimers Dis. 2009. PMID: 19363256 Free PMC article. Review.